BioSpace News Archive

Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) (“Dermata” or the “Company”), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that it successfully enrolled the first patient in its pivotal DMT310 Phase 3 Spongilla Treatment for Acne Research (STAR-1) study.

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference.

Immunovant, Inc. (Nasdaq: IMVT) today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical trial of batoclimab in patients with Graves’ disease meaningfully exceeded 50% response rates.

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) (“Calliditas”), today announced that the U.S. Food and Drug Administration (FDA) has approved TARPEYO (budesonide) delayed release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.

Merck (NYSE: MRK) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Merck’s New Drug Application (NDA) for gefapixant, an investigational, non-narcotic, oral selective P2X3 receptor antagonist, under development for the treatment of refractory chronic cough (RCC) or unexplained chronic cough (UCC) in adults.

Annexon, Inc. (Nasdaq: ANNX) today reported results from the Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) healthy volunteer study of ANX1502, a first-in-kind oral, selective small molecule inhibitor that targets the active form of C1s responsible for propagating classical pathway activation in association with C1q.

Kriya Therapeutics, Inc. (“Kriya”) today announced that Shankar Ramaswamy, M.D., Co-Founder and CEO, will present at the J.P. Morgan 42nd Annual Healthcare Conference on Tuesday, January 9th, at 9:00 AM PT in San Francisco, California.

Shockwave Medical, Inc. (NASDAQ: SWAV) announced today that the company will be participating in the 42nd Annual J.P. Morgan Healthcare Conference, which is being held from Monday, January 8 to Thursday, January 11, 2024, in San Francisco, CA.

Tenon Medical, Inc. (“Tenon” or the “Company”) (NASDAQ:TNON), a company transforming care for patients suffering with certain sacroiliac joint disorders, today announced participation in two recent immersive physician webinar training programs featuring the Company’s Catamaran SI Joint Fusion System.

Meilleur Technologies Inc. announced it has signed an agreement with PharmaLogic Holdings Corporation granting PharmaLogic the rights to manufacture fluorine-18 [F18]NAV4694, a next-generation investigational imaging biomarker used in Positron Emission Tomography imaging studies to assess the status of amyloid plaque in the brain.